To investigate the application value of ¹³C-urea breath test(¹³C-UBT) in the diagnosis and efficacy evaluation of helicobacter pylori(Hp) infection.

Three hundred forty-six cases patients with gastrointestinal diseases from January 2013 to December 2014 were selected as research subjects(gastrointestinal disease group) and detected by ¹³C-UBT.One hundred cases patients of non-gastrointestinal diseases were selected as control group and detected by ¹³C-UBT too.The Hp positive rate between the two group were compared, then the Hp-positive patients were randomly divided into ⅠGroup (PPI triple therapy) and Ⅱ group (PPI quadruple therapy), two weeks for a course.After treatment, ¹³C-UBT were conducted, the Hp negative rate as evaluation index curative effect were analyzed.The adverse reactions in the process of treatment were observed

Hp positive rate of gastrointestinal diseases group were 59.83%(207/346), significantly higher than that of the control group 2.00%(2/100), the difference was statistically significant(χ²=104.177, P<0.01). Two hundred and seven cases patients with Hp positive were randomly divided into Ⅰgroup (PPI triple therapy) with 103 cases and Ⅱ group(PPI quadruple therapy) with 104 cases, the Hp eradication rate of Ⅰgroup were 74.76%(77/103), significantly lower than that of Ⅱ group 95.19%(99/104), the difference was statistically significant(χ²=16.971, P<0.01). The total effective rate in Ⅰgroup were 89.32%(92/103), significantly lower than that of Ⅱ group 98.08%(102/104), the difference was statistically significant(z=-6.111, P<0.01).

¹³C-UBT has unique advantage in the diagnosis of Hp infection and guidance standard medication, can improve the diagnostic rate of Hp positive rate, effective judge the HP eradication efficacy.PPI quadruple therapy is recommended as the preferred for Hp-positive patients to improve the Hp eradication rate by 13-CBT.

Helicobacter pylori; ¹³C-urea breath test; Diagnosis; Quadruple therapy; Efficacy evaluation